Ebola virus convalescent blood products: Where we are now and where we may need to go

Blajchman, 2009, Protecting the blood supply from emerging pathogens: the role of pathogen inactivation, Transfus Clin Biol, 16, 70, 10.1016/j.tracli.2009.04.004 Dodd, 2012, Emerging pathogens and their implications for the blood supply and transfusion transmitted infections, Br J Haematol, 159, 135, 10.1111/bjh.12031 Breban, 2013, Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk, Lancet, 382, 694, 10.1016/S0140-6736(13)61492-0 Wong, 2003, Treatment of severe acute respiratory syndrome with convalescent plasma, Hong Kong Med J, 9, 199 Kong, 2006, Successful treatment of avian influenza with convalescent plasma, Hong Kong Med J, 12, 489 Leider, 2010, Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?, Transfusion, 50, 1384, 10.1111/j.1537-2995.2010.02590.x Zingher, 2005, Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180–1187, Rev Med Virol, 15, 407, 10.1002/rmv.480 Luke, 2006, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann Intern Med, 145, 599, 10.7326/0003-4819-145-8-200610170-00139 Gunn, 1932, Convalescent serum in prophylaxis of measles, chicken-pox, and mumps, Br Med J, 1, 183, 10.1136/bmj.1.3708.183 Anonymous, 2014 WHO, 2014 Gulland, 2014, First Ebola treatment is approved by WHO, Br Med J, 349, g5539, 10.1136/bmj.g5539 Mupapa, 1999, Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee, J Infect Dis, 179, S18, 10.1086/514298 Emond, 1977, A case of Ebola virus infection, Br Med J, 2, 541, 10.1136/bmj.2.6086.541 Parren, 2002, Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody, J Virol, 76, 6408, 10.1128/JVI.76.12.6408-6412.2002 Macneil, 2011, Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus, PLoS Negl Trop Dis, 5, e1175, 10.1371/journal.pntd.0001175 Takada, 2007, Epitopes required for antibody-dependent enhancement of Ebola virus infection, J Infect Dis, 196, S347, 10.1086/520581 Takada, 2003, Antibody-dependent enhancement of Ebola virus infection, J Virol, 77, 7539, 10.1128/JVI.77.13.7539-7544.2003 Geisbert, 2002, Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections, Virology, 293, 15, 10.1006/viro.2001.1279 McGuire, 1918, The use of convalescent human serum in influenza pneumonia-a preliminary report, Am J Public Health, 8, 741, 10.2105/AJPH.8.10.741 Parry, 2012, Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy, Vox Sang, 103, 107, 10.1111/j.1423-0410.2012.01599.x Gundersen, 1935, Convalescent blood for herpes zoster, Trans Am Ophthalmol Soc, 33, 508 Jensen, 1935, The 1934 Epidemic of poliomyelitis in Denmark. Preliminary report on the epidemiology, clinical features and convalescent serum therapy: (section of pathology), Proc R Soc Med, 28, 1007 Dewar, 1946, Treatment of typhoid fever with convalescent whole blood, J R Army Med Corps, 86, 249 Nabarro, 1931, Convalescent serum in prophylaxis of measles, Br Med J, 1, 12, 10.1136/bmj.1.3652.12 Avenard, 1979, The prevention of chickenpox in high risk children. Comparison of the effectiveness of specific immunoglobulins and of defibrinated convalescent plasma. 414 cases (author's transl), Nouv Presse Med, 8, 673 Wong, 2010, Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection, Transfusion, 50, 1967, 10.1111/j.1537-2995.2010.02651.x Maiztegui, 1979, Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome, Lancet, 2, 1216, 10.1016/S0140-6736(79)92335-3 Cheng, 2005, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, 24, 44, 10.1007/s10096-004-1271-9 Mair-Jenkins, 2014, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis Soo, 2004, Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients, Clin Microbiol Infect, 10, 676, 10.1111/j.1469-0691.2004.00956.x Yeh, 2005, Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital, J Antimicrob Chemother, 56, 919, 10.1093/jac/dki346 Hung, 2011, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis, 52, 447, 10.1093/cid/ciq106 Zhou, 2007, Treatment with convalescent plasma for influenza A (H5N1) infection, N Engl J Med, 357, 1450, 10.1056/NEJMc070359 Frame, 1984, The use of Lassa fever convalescent plasma in Nigeria, Trans R Soc Trop Med Hyg, 78, 319, 10.1016/0035-9203(84)90107-X Mohr, 1993, Methylene blue/light treatment of virus inactivated human plasma: production and clinical experience, Infusionsther Transfusionsmed, 20, 19 Singh, 2006, Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function, Transfusion, 46, 1168, 10.1111/j.1537-2995.2006.00867.x Bihm, 2010, Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30 degrees C, Vox Sang, 98, 108, 10.1111/j.1423-0410.2009.01238.x Klein, 2005, Pathogen inactivation technology: cleansing the blood supply, J Intern Med, 257, 224, 10.1111/j.1365-2796.2005.01451.x Rock, 2011, A comparison of methods of pathogen inactivation of FFP, Vox Sang, 100, 169, 10.1111/j.1423-0410.2010.01374.x Solheim, 2006, Update on pathogen reduction technology for therapeutic plasma: an overview, Transfus Apher Sci, 35, 83, 10.1016/j.transci.2006.02.004 El-Ekiaby, 2010, Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system, Transfus Med, 20, 48, 10.1111/j.1365-3148.2009.00963.x Goubran, 2000, Virucidal heat-treatment of single plasma units: a potential approach for developing countries, Haemophilia, 6, 597, 10.1046/j.1365-2516.2000.00435.x Watt, 2001, Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study, QJM, 94, 599, 10.1093/qjmed/94.11.599 Watt, 2000, HIV-1 suppression during acute scrub-typhus infection, Lancet, 356, 475, 10.1016/S0140-6736(00)02557-5 Vittecoq, 1992, Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma, J Infect Dis, 165, 364, 10.1093/infdis/165.2.364 Vittecoq, 1995, Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma, Proc Natl Acad Sci U S A, 92, 1195, 10.1073/pnas.92.4.1195 Burnouf, 2003, Nanofiltration of single plasma donations: feasibility study, Vox Sang, 84, 111, 10.1046/j.1423-0410.2003.00265.x El-Ekiaby, 2009, New methods of plasma fractionation – a presentation of the ‘mini-pool’ fractionation procedure developed in Egypt, ISBT Science Series, 4, 99, 10.1111/j.1751-2824.2009.01218.x Dichtelmuller, 2002, Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution, Biologicals, 30, 135, 10.1006/biol.2002.0332 Korneyeva, 2002, Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates, Biologicals, 30, 153, 10.1006/biol.2002.0334 El-Ekiaby, 2014, Clinical evaluation of minipool immunoglobulin plasma fraction in primary immunodeficiency patients. 5A-S42-02, Vox Sang, 107, 1 Solheim, 2009, Pathogen Inactivation BRN WBRN, 2014 Burnouf, 2007, Modern plasma fractionation, Transfus Med Rev, 21, 101, 10.1016/j.tmrv.2006.11.001 Radosevich, 2010, Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance, Vox Sang, 98, 12, 10.1111/j.1423-0410.2009.01226.x WHO, 2007, Annex 4. Recommendations for the collection, quality control and regulation of human plasma for fractionation, WHO Tech Rep Ser, 941, 189 Sabchareon, 1991, Parasitological and clinical human response to immunoglobulin administration in falciparum-malaria, Am J Trop Med Hyg, 45, 297, 10.4269/ajtmh.1991.45.297 Zhang, 2005, Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma, Transfusion, 45, 1160, 10.1111/j.1537-2995.2005.00179.x Planitzer, 2007, West Nile virus neutralization by US plasma-derived immunoglobulin products, J Infect Dis, 196, 435, 10.1086/519392 Rabel, 2011, Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010, Euro Surveill, 16, 10.2807/ese.16.10.19812-en Farcet, 2010, Hepatitis A virus antibodies in immunoglobulin preparations, J Allergy Clin Immunol, 125, 198, 10.1016/j.jaci.2009.09.008 Audet, 2006, Measles-virus–neutralizing antibodies in intravenous immunoglobulins, J Infect Dis, 194, 781, 10.1086/506363 Burnouf, 2014, Ebola: a call for blood transfusion strategy in sub-Saharan Africa, Lancet, 384, 1347, 10.1016/S0140-6736(14)61693-7 WHO, 2014